Literature DB >> 11942927

Randomized controlled trials in schizophrenia: a critical perspective on the literature.

S Gilbody1, K Wahlbeck, C Adams.   

Abstract

OBJECTIVE: The randomized trial provides an opportunity to minimize the inclusion of biases in the evaluation of interventions in psychiatry. Difficulties arise, however, when applying their results to 'real world' clinical practice and decision-making. We, therefore, examined the real world applicability of schizophrenia trials.
METHOD: A narrative overview of the content and quality of the randomized trials relevant to the care of those with schizophrenia is provided.
RESULTS: Complex, explanatory, under-powered randomized drug trials dominate evaluative research in schizophrenia.
CONCLUSION: Explanatory designs are a necessary but insufficient step in establishing the true worth of interventions in schizophrenia. Research from other spheres of mental health and wider health care suggest that pragmatic trials are feasible. This design allows large scale trials to be conducted which include patients which we would recognize from routine practice and which record outcomes which are of genuine interest to decision-makers.

Entities:  

Mesh:

Year:  2002        PMID: 11942927     DOI: 10.1034/j.1600-0447.2002.00242.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  13 in total

1.  Psychotropic combination in schizophrenia.

Authors:  E Acquaviva; I Gasquet; B Falissard
Journal:  Eur J Clin Pharmacol       Date:  2005-11-08       Impact factor: 2.953

2.  The quest for a meaningful evidence base in psychiatry.

Authors:  Robin Emsley; Sue Hawkridge
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

3.  Are psychiatrists an endangered species? Observations on internal and external challenges to the profession.

Authors:  Heinz Katschnig
Journal:  World Psychiatry       Date:  2010-02       Impact factor: 49.548

4.  The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial.

Authors:  Reinhold Kilian; Matthias C Angermeyer
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

5.  Symptoms of Depression, Positive Symptoms of Psychosis, and Suicidal Ideation Among Adults Diagnosed With Schizophrenia Within the Clinical Antipsychotic Trials of Intervention Effectiveness.

Authors:  Lindsay A Bornheimer; James Jaccard
Journal:  Arch Suicide Res       Date:  2016-08-23

6.  A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England.

Authors:  Kinan Mokbel; Rob Daniels; Michael N Weedon; Leigh Jackson
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

7.  External validity of studies on aggressive behavior in patients with schizophrenia: systematic review.

Authors:  Tilman Steinert; Karen Hamann
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-08-23

8.  Antipsychotics dosage and antiparkinsonian prescriptions.

Authors:  Eric Acquaviva; Isabelle Gasquet; Bruno Falissard
Journal:  Clin Pract Epidemiol Ment Health       Date:  2007-09-03

9.  The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset.

Authors:  Katrina Witt; Keith Hawton; Seena Fazel
Journal:  Schizophr Res       Date:  2014-02-26       Impact factor: 4.939

Review 10.  Clinical and economic burden of adverse drug reactions.

Authors:  Janet Sultana; Paola Cutroneo; Gianluca Trifirò
Journal:  J Pharmacol Pharmacother       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.